These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19596127)

  • 21. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients.
    Debouverie M; Laforest L; Van Ganse E; Guillemin F;
    Mult Scler; 2009 Feb; 15(2):251-7. PubMed ID: 19181774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis.
    Smolders J; Thewissen M; Theunissen R; Peelen E; Knippenberg S; Menheere P; Cohen Tervaert JW; Hupperts R; Damoiseaux J
    J Neuroimmunol; 2011 Jun; 235(1-2):91-7. PubMed ID: 21507492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis.
    Cossburn M; Ingram G; Hirst C; Ben-Shlomo Y; Pickersgill TP; Robertson NP
    Mult Scler; 2012 Jan; 18(1):45-54. PubMed ID: 21865412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse.
    Moshirzadeh S; Ghareghozli K; Harandi AA; Pakdaman H
    J Clin Neurosci; 2012 Apr; 19(4):622-3. PubMed ID: 22341909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Khalil M; Enzinger C; Langkammer C; Tscherner M; Wallner-Blazek M; Jehna M; Ropele S; Fuchs S; Fazekas F
    Mult Scler; 2009 Sep; 15(9):1048-54. PubMed ID: 19556316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A subtype of multiple sclerosis defined by an activated immune defense program.
    van Baarsen LG; van der Pouw Kraan TC; Kragt JJ; Baggen JM; Rustenburg F; Hooper T; Meilof JF; Fero MJ; Dijkstra CD; Polman CH; Verweij CL
    Genes Immun; 2006 Sep; 7(6):522-31. PubMed ID: 16837931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
    Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
    Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous task shift processes in relapsing-remitting multiple sclerosis.
    Stablum F; Meligrana L; Sgaramella T; Bortolon F; Toso V
    Brain Cogn; 2004 Dec; 56(3):328-31. PubMed ID: 15522771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-beta(1b) treatment in neuromyelitis optica.
    Tanaka M; Tanaka K; Komori M
    Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
    Freedman MS; Hughes B; Mikol DD; Bennett R; Cuffel B; Divan V; LaVallee N; Al-Sabbagh A
    Eur Neurol; 2008; 60(1):1-11. PubMed ID: 18437041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orbicularis oculi reflex abnormalities in patients with multiple sclerosis: a clinical, EMG, and MRI investigation.
    Klissurski M; Novachkova S; Tzvetanov P; Alexiev F
    Electromyogr Clin Neurophysiol; 2009; 49(1):59-63. PubMed ID: 19280801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cognitive evoked potentials in remitting-relapsing and benign forms of multiple sclerosis].
    Vázquez-Marrufo M; González-Rosa J; Vaquero-Casares E; Duque P; Borges M; Izquierdo G
    Rev Neurol; 2009 May 1-15; 48(9):453-8. PubMed ID: 19396761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age at onset determines the occurrence of the progressive phase of multiple sclerosis.
    Stankoff B; Mrejen S; Tourbah A; Fontaine B; Lyon-Caen O; Lubetzki C; Rosenheim M
    Neurology; 2007 Mar; 68(10):779-81. PubMed ID: 17339588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
    J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.